This study tests a new treatment for relapsing-remitting multiple sclerosis (MS) that uses a patient's own immune cells (dendritic cells) to calm the immune system and reduce attacks. The therapy is given alongside standard MS medications. The trial involves 45 adults aged 18-65 …
Phase: PHASE2 • Sponsor: Judit Pich • Aim: Disease control
Last updated May 07, 2026 18:39 UTC